Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.50 |
| ▸ | VIPR2 | P41587 | 7/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 2/20 | 0.48 |
| ▸ | NPY2R | P49146 | 2/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | NMBR | P28336 | 1/20 | 0.47 |
| ▸ | GRPR | P30550 | 1/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433159 | 0.96 | KDM1A (0.56) | KDM1AMAOBKDM5AKDM1BVIPR2 | |
| SCHEMBL30438112 | 0.85 | NTSR2 (0.53) | KDM1A | |
| SCHEMBL31688326 | 0.85 | KDM1A (0.58) | KDM1AMAOBKDM5AKDM1BVIPR2 | |
| SCHEMBL29779794 | 0.85 | NTSR2 (0.53) | — | |
| SCHEMBL2979904 | 0.83 | KDM1A (0.53) | KDM1AMAOBKDM5AKDM1B | |
| SCHEMBL30262063 | 0.82 | VIPR2 (0.54) | KDM1AMAOBKDM5AKDM1BVIPR2 | |
| SCHEMBL31182913 | 0.81 | KDM1A (0.59) | KDM1AMAOBKDM5AKDM1BNPY1R | |
| SCHEMBL29939531 | 0.81 | BACE1 (0.53) | KDM1AMAOBKDM5AKDM1BTFPI | |
| SCHEMBL29612189 | 0.81 | KDM1A (0.55) | KDM1AMAOBKDM5AKDM1B | |
| SCHEMBL11579186 | 0.81 | KDM1A (0.51) | KDM1AMAOBKDM5AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074946-A1 | USE OF SE-DR AFFINITY PEPTIDE IN PREPARING DRUG FOR TREATING RHEUMATIC DISEASE | Hebei Fitness Biotechnology Co., Ltd. (CN) | 2025-03-06 | — | — | US | claimed |
| EP-4378471-A1 | USE OF SE-DR AFFINITY PEPTIDE IN PREPARING DRUG FOR TREATING RHEUMATIC DISEASE | Hebei Fitness Biotechnology Co., Ltd. (CN) | 2024-06-05 | — | — | EP | claimed |
| CN-117883547-A | Application of SE-DR affinity peptide in preparation of medicines for treating rheumatism | 河北菲尼斯生物技术有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-116528882-A | Peptides for use in immunotherapeutic agents | 3H生物有限公司 | 2023-08-01 | — | — | CN | claimed |
| EP-4186916-A1 | PEPTIDE FOR IMMUNOTHERAPEUTIC AGENT | 3H Bio. Co., Ltd. (KR) | 2023-05-31 | — | — | EP | claimed |
| US-20230134067-A1 | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS | 3H BIO. CO., LTD. (KR) | 2023-05-04 | — | — | US | claimed |
| US-20230087676-A1 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | 3H BIO. CO., LTD. (KR) | 2023-03-23 | — | — | US | claimed |
| CN-115671253-A | Application of SE-DR affinity peptide in preparing medicine for treating rheumatic diseases | 河北菲尼斯生物技术有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2023006125-A1 | USE OF SE-DR AFFINITY PEPTIDE IN PREPARING DRUG FOR TREATING RHEUMATIC DISEASE | 河北菲尼斯生物技术有限公司 | 2023-02-02 | — | — | WO | claimed |
| US-20260137767-A1 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | VIROMETIX AG (CH) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107186-A1 | COMPOSITIONS, SYSTEMS AND METHODS RELATING TO THE IDENTIFICATION OF HLA CLASS II-BINDING PEPTIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260130992-A1 | NANOPARTICLES FOR DELIVERY OF IMMUNOREGULATORY MATERIALS TO T CELLS | UNIV JOHNS HOPKINS (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624349-B2 | Methods of high-throughput identification of T cell epitopes by capturing cytokines on the surface of antigen-presenting cells | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260061054-A1 | NANOPARTICLES FOR DELIVERY OF IMMUNOREGULATORY MATERIALS TO T CELLS | UNIV JOHNS HOPKINS (US) | 2026-03-05 | — | — | US | disclosed |
| CN-109265543-B | Protein-based therapy and diagnosis of TAU protein-mediated pathologies in alzheimer's disease | 阿克松神经系统科学公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220106378-A1 | T-CELL MODULATORY ANTIGEN-PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220090138-A1 | MODIFIED ADENOVIRUSES | SEATTLE PROJECT CORP. | 2022-03-24 | — | — | US | disclosed |
| EP-3952905-A1 | CELL | Autolus Limited (GB) | 2022-02-16 | — | — | EP | disclosed |
| US-11248051-B2 | Administration of agents for the treatment of inflammation | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022026926-A1 | TARGET-RECOGNITION OF ANTIGEN-MHC COMPLEX REPORTER (TRACER) PLATFORM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130992-A1 | NANOPARTICLES FOR DELIVERY OF IMMUNOREGULATORY MATERIALS TO T CELLS | MICA, HLA-DRB1, HLA-C | KDM1A 2461/4885MAOB 3524/4885KDM5A 2122/4885 |
| US-20260137767-A1 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | VSIR, LRBA, CD74 | KDM1A 1338/4885MAOB 4758/4885KDM5A 1301/4885 |
| US-20260061054-A1 | NANOPARTICLES FOR DELIVERY OF IMMUNOREGULATORY MATERIALS TO T CELLS | HLA-C, CD74, HLA-B | KDM1A 2847/4885MAOB 2812/4885KDM5A 2641/4885 |
| US-12624349-B2 | Methods of high-throughput identification of T cell epitopes by capturing cytokines on the surface of antigen-presenting cells | MICA, HLA-DRB1, CD74 | KDM1A 4562/4885MAOB 4770/4885KDM5A 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.